Randomized, double blind, placebo controlled phase III evaluation of cisplatin + placebo versus cisplatin + C225 a mouse/human monoclonal antibody to the epidermal growth factor receptor, in patients with metastatic and/or recurrent squamous cell cancer of the head and neck
Phase of Trial: Phase III
Latest Information Update: 31 Aug 2010
At a glance
- Drugs Cetuximab (Primary) ; Cisplatin
- Indications Head and neck cancer
- Focus Therapeutic Use
- 31 Aug 2010 Planned end date (October 2010) added as reported by ClinicalTrials.gov.
- 12 Sep 2005 New trial record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History